Amicus Therapeutics (FOLD) Shares Gap Down to $16.40

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) gapped down before the market opened on Monday . The stock had previously closed at $16.78, but opened at $16.40. Amicus Therapeutics shares last traded at $15.88, with a volume of 3908225 shares traded.

A number of analysts have recently weighed in on the company. ValuEngine raised Amicus Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Zacks Investment Research raised Amicus Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, January 17th. BidaskClub raised Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, January 15th. Finally, Cowen reaffirmed a “buy” rating and set a $22.00 price objective on shares of Amicus Therapeutics in a research report on Wednesday, January 10th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Amicus Therapeutics has a consensus rating of “Buy” and an average price target of $18.31.

The company has a market cap of $2,640.36, a price-to-earnings ratio of -9.05 and a beta of 1.46. The company has a current ratio of 6.32, a quick ratio of 6.22 and a debt-to-equity ratio of 0.39.

Amicus Therapeutics (NASDAQ:FOLD) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.10). The business had revenue of $10.90 million during the quarter, compared to analysts’ expectations of $9.02 million. Amicus Therapeutics had a negative net margin of 1,092.37% and a negative return on equity of 63.54%. The business’s quarterly revenue was up 419.0% compared to the same quarter last year. During the same period last year, the company earned ($0.33) EPS. sell-side analysts forecast that Amicus Therapeutics, Inc. will post -1.52 EPS for the current year.

In other Amicus Therapeutics news, CEO John F. Crowley sold 65,581 shares of the firm’s stock in a transaction dated Thursday, December 21st. The stock was sold at an average price of $13.51, for a total transaction of $885,999.31. Following the transaction, the chief executive officer now owns 393,076 shares of the company’s stock, valued at $5,310,456.76. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Jay Barth sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, January 23rd. The stock was sold at an average price of $16.80, for a total value of $336,000.00. Following the transaction, the insider now directly owns 105,409 shares in the company, valued at approximately $1,770,871.20. The disclosure for this sale can be found here. Insiders sold 250,390 shares of company stock worth $3,620,581 in the last three months. 3.40% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently made changes to their positions in the company. Strs Ohio acquired a new stake in shares of Amicus Therapeutics during the third quarter worth about $102,000. Tudor Investment Corp ET AL acquired a new stake in shares of Amicus Therapeutics during the second quarter worth about $124,000. Birchview Capital LP acquired a new stake in shares of Amicus Therapeutics during the third quarter worth about $151,000. Sage Capital Advisors llc acquired a new stake in shares of Amicus Therapeutics during the third quarter worth about $154,000. Finally, Engineers Gate Manager LP acquired a new stake in shares of Amicus Therapeutics during the third quarter worth about $155,000.

TRADEMARK VIOLATION WARNING: This report was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://www.com-unik.info/2018/02/07/amicus-therapeutics-fold-shares-gap-down-to-16-40.html.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit